Efficacy and Safety of Trastuzumab-rezetecan in HER2-Expressing Breast Cancer — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Efficacy and Safety of Trastuzumab-rezetecan in HER2-Expressing Breast Cancer — Stella

Recruiting

Back to Trastuzumab-rezetecan trials

Trial locations(1 site)

China

Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong

Key details

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Enrollment target

~300 participants

Started

June 2025

Primary completion

June 2029

Age range

18 Years and older

Last updated January 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov